<div id="readability-page-1"><p>In a report released yesterday, Geoff Meacham from Citi maintained a Buy rating on BioNTech SE, with a price target of <span id="expert-recommendation-target">$145.00</span>. The company’s shares closed yesterday at $95.85.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly &amp; Co, Bristol-Myers Squibb, and BioNTech SE. According to TipRanks, Meacham has an average return of <span>8.0%</span> and a 55.46% success rate on recommended stocks. </p> <p>BioNTech SE has an analyst consensus of Strong Buy, with a price target consensus of $141.57.</p></div>

BNTX

<p>Citi analyst Geoff Meacham maintains a Buy rating for BioNTech SE with a price target of $145. Shares closed at $95.85. Meacham, covering the Healthcare sector, has an average return of 8.0% and a 55.46% success rate. BioNTech SE has a Strong Buy consensus with a price target of $141.57.</p>

Citi Sticks to Their Buy Rating for BioNTech SE (BNTX)